|
54th Annual Meeting of
The American Association for
the Study of Liver Diseases
October 24, 28- 2003
Boston, Massachusetts
INDEX
| |
Page One |
| |
|
| |
http://www.hivandhepatitis.com
|
| |
|
HIV-HCV
Coinfection |
|
Efficacy of Pegasys vs Pegasys
Plus Ribavirin in HIV-HCV Coinfected Patients Who Are Nonresponders to
Prior Interferon Therapy
10/27/03
Host Factors Responsible for a Viral Response May Be Different in
Responders Compared with Nonresponders and Independent of Serum
PEG-Intron Concentrations
10/27/03
HIV-HBV Coinfected Patients Show Sustained Suppression of
Epivir-HBV-resistant HBV Through 3 Years of Treatment with Hepsera
10/29/03
Report Confirms
Safety of Liver Transplantation in HIV-HCV Co-infected Patients
10/29/03
GB
Virus C (GBV-C) Clearance Is Frequent in HIV-HCV Coinfected Patients
Receiving Interferon and Ribavirin and Does Not Elevate HIV RNA Levels
10/29/03
HIV-HCV Coinfection Status Does Not Affect HCV Viral Kinetic Response to
Interferon
11/10/03
Page Two |
|
Sustained Viral Response (SVR) |
|
Viral Kinetics Can
Predict Sustained Viral Response to Treatment with Pegasys and
Ribavirin, independent of Genotype, as Early as 1 or 4 Weeks of
Treatment
10/27/03
A Comparison of Standard Treatment
Versus Dynamically Individualized Treatment in Patients with Chronic
Hepatitis C
10/27/03
Ribavirin Dosage
Significantly Affects Virological Response Rates in HCV Patients Treated
with Interferon/Ribavirin
10/27/03
Preliminary Data Do Not Support
Hypothesis That Higher SVR Rates in Genotype 1 HCV Patients Result from
Extending Treatment from 48 to 72 Weeks
10/27/03
Patients with Increased Symptoms of Depression During
Interferon/Ribavirin Therapy Are Less Likely to Clear HCV
10/27/03
Age
and Adherence Are Significant Predictors of HCV Treatment Success
10/29/03
RANTES
Haplotypes Predictive of Sustained Virological Response to HCV Treatment
10/31/03
Results of
Long-term Follow Up of Sustained Responders to Interferon Therapy in
Chronic HCV Patients: A Meta-analysis
11/10/03
A Dynamic
Model to Predict Sustained Virological Response to Combination Treatment
with Pegasys and Copegus in Patients with Chronic HCV
11/19/03
Page Three
|
|
Genotypes |
|
Viral Kinetics Can
Predict Sustained Viral Response to Treatment with Pegasys and
Ribavirin, independent of Genotype, as Early as 1 or 4 Weeks of
Treatment
10/27/03
Pegasys/Ribavirin
Treatment in African American and Caucasians with Chronic HCV Genotype 1
10/27/03
Pegasys/Ribavirin Enhances HCV
Specific T-cell Responses by Restoration of Dendritic Cell Functions
10/27/03
Preliminary Data Do Not Support
Hypothesis That Higher SVR Rates in Genotype 1 HCV Patients Result from
Extending Treatment from 48 to 72 Weeks
10/27/03
Subjects with Chronic Hepatitis C
and Genotype 4 Have a Similarly Effective Response to Standard or
Pegylated Interferon in Combination with Ribavirin
10/27/03
Rapid Viral Decline with Pegasys/Ribavirin in HCV Genotype 1 Is
Associated with Enhanced HCV-specific T-cell Reactivity
10/29/03
Pegasys Plus
Ribavirin Demonstrates Good Safety and Tolerability Profiles in African
Americans with Chronic HCV Genotype 1
11/03/03
Pegasys Plus
Ribavirin Produces a Benefit Regarding Histologic Response Among African
Americans and Caucasians with Chronic HCV Genotype 1
11/03/03
Combination
Treatment with Pegasys and Copegus Significantly Enhances Sustained
Virological and Biochemical Response Rates in Patients with Chronic
Hepatitis C Genotype 4
11/05/03
Daily and
Higher Initial Dosing of Consensus Interferon (Infergen) May Be a
Worthwhile Alternative to Peginterferon + Ribavirin in Genotype 1 HCV
Patients with High HCV RNA
11/07/03
Racial Differences in HCV Disease Severity Between African American and
Caucasian American Patients with HCV Genotype 1
11/19/03
Page Four
|
|
Viral
Kinetics |
|
Viral Kinetics Can
Predict Sustained Viral Response to Treatment with Pegasys and
Ribavirin, independent of Genotype, as Early as 1 or 4 Weeks of
Treatment
10/27/03
A Comparison of Standard Treatment Versus Dynamically Individualized
Treatment in Patients with Chronic Hepatitis C
10/27/03
Rapid Viral Decline with Pegasys/Ribavirin in HCV Genotype 1 Is
Associated with Enhanced HCV-specific T-cell Reactivity
10/29/03
HIV-HCV
Coinfection Status Does Not Affect HCV Viral Kinetic Response to
Interferon
11/10/03
Multivariate Models Predict Outcome of Therapy for HCV at Baseline and
at Weeks 4 and 8
11/07/03
HIV-HCV
Coinfection Status Does Not Affect HCV Viral Kinetic Response to
Interferon
11/10/03
Page Five |
|
Nonresponders and Relapsers |
|
A Comparison of
Standard Treatment Versus Dynamically Individualized Treatment in
Patients with Chronic Hepatitis C
10/27/03
Treatment with
PEG-Intron Plus Ribavirin Is Effective in 50% of Relapsers to Standard
Combination Therapy
10/27/03
Treatment with PEG-Intron and Ribavirin Produces Significant Sustained
Virologic Response Rates in Patients Who Failed Prior Therapy
10/27/03
Weight-based Dosing of PEG-Intron
or Double the Dose Plus Ribavirin for Naïve Patients and Double Dose
PEG-Intron Plus Ribavirin for Nonresponders and Relapsers
10/27/03
Efficacy of Pegasys vs Pegasys
Plus Ribavirin in HIV-HCV Coinfected Patients Who Are Nonresponders to
Prior Interferon Therapy
10/27/03
Host Factors Responsible for a Viral Response May Be Different in
Responders Compared with Nonresponders and Independent of Serum
PEG-Intron Concentrations
10/27/03
Delivery of
Consensus Interferon (Infergen) by Continuous Pump Shows Substantial
Reduction of HCV RNA Levels Among Nonresponder HCV Patients
11/07/03
61% of Prior
Nonresponders Experience Early Virological Response after 12 Weeks of
Triple Therapy with Zadaxin (thymalfasin) + Pegasys + Ribavirin: Interim
Results of a Pilot Study
11/10/03
In
Nonresponders at Week 48, High Dose PEG-Intron (3.0 mcg/kg/wk) Plus
Ribavirin Produces Similar Viral Clearance Rate as Standard Dose (1.5
mcg/kg/wk): The Renew Trial
11/17/03
HCV-specific
Immune Responses at Baseline Do Not Predict a Favorable Retreatment
Outcome in Patients with Advanced Disease
11/21/03
Page Six
|
|
Tests
(ALT, AST, etc) |
|
Treatment Response
to Pegasys/Ribavirin Among Chronic HCV Patients with Normal ALT Levels
Is Similar to That Obtained Among Patients with Elevated ALT
10/27/03
Untreated Patients
with Chronic Hepatitis C (CHC) and Normal ALT Levels Have Distinct
Biological and Virological Features and a Majority Report CHC Symptoms
Associated with Interferon Treatment
10/27/03
Patients with Chronic Hepatitis C
and Normal ALT Levels Show Impaired Quality of Life But Significantly
Lower Liver Inflammation and Fibrosis Progression Compared to Patients
with Elevated ALT
10/27/03
ALT Flares
Are Not Necessary for a Significant Response to Therapy with Roferon or
Pegasys in Patients with HBeAg positive Chronic Hepatitis B
11/05/03
Daily and Higher
Initial Dosing of Consensus Interferon (Infergen) May Be a Worthwhile
Alternative to Peginterferon + Ribavirin in Genotype 1 HCV Patients with
High HCV RNA
11/07/03
In
Patients 65 Years or Older, Chronic HCV Is More Severe and Presents with
Lower ALT Levels Than in Younger Patients
11/10/03
Qualitative
Tests (QLFTS) Detect Impaired Hepatic Function in a High Proportion of
Patients with Chronic HCV and Fibrosis or Cirrhosis and May Predict Risk
of Cirrhosis, Splenomegaly and Varices
11/17/03
Page Seven |
|
African
Americans |
|
|
Pegasys/Ribavirin
Treatment in African American and Caucasians with Chronic HCV Genotype 1
10/27/03
Pegasys Plus Ribavirin Demonstrates Good Safety
and Tolerability Profiles in African Americans with Chronic HCV Genotype
1
11/03/03
Pegasys Plus
Ribavirin Produces a Benefit Regarding Histologic Response Among African
Americans and Caucasians with Chronic HCV Genotype 1
11/03/03
Racial Differences in HCV Disease Severity Between African American and
Caucasian American Patients with HCV Genotype 1
11/19/03 |
|
Pathogenesis |
|
|
Pegasys/Ribavirin
Enhances HCV Specific T-cell Responses by Restoration of Dendritic Cell
Functions
10/27/03
|
|
Toxicities and Side Effects |
|
Untreated Patients
with Chronic Hepatitis C (CHC) and Normal ALT Levels Have Distinct
Biological and Virological Features and a Majority Report CHC Symptoms
Associated with Interferon Treatment
10/27/03
Patients with Increased Symptoms
of Depression During Interferon/Ribavirin Therapy Are Less Likely to
Clear HCV
10/27/03
Peginterferon Commonly Causes
Clinically Significant Depressive Symptoms, but Not Major Depression,
and Ribavirin May Contribute to Depression in a Dose-dependent Manner
10/27/03
Visual
Problems May Not Completely Resolve in All Patients After Discontinuing
Treatment with Peginterferon and Ribavirin: Observations from the WIN-R
Trial
11/10/03
Viramidine,
a Prodrug of Ribavirin, May Have Increased Efficacy and Reduced Red
Blood Cell Toxicity Compared to Ribavirin
11/14/03
|
Adverse Drug Reactions: liver toxicity |
|
Predictors
of Antiretroviral-related Severe Liver Toxicity in 21 AACTG Studies
11/07/03
Description
of Liver Toxicity Associated with HIV Protease Inhibitors with or
without Low-dose Ritonavir Boosting
11/07/03
Page Eight |
|
Ribavirin Issues |
|
Ribavirin Dosage
Significantly Affects Virological Response Rates in HCV Patients Treated
with Interferon/Ribavirin
10/27/03
Peginterferon Commonly Causes
Clinically Significant Depressive Symptoms, but Not Major Depression,
and Ribavirin May Contribute to Depression in a Dose-dependent Manner
10/27/03
At 24 Weeks,
a Ribavirin Dose of 1000mg/day Appears to Offer No Advantages Over a
Dose of 800mg/day in HIV-HCV Coinfected Patients
11/10/03
Page Nine |
|
Dosing |
|
Ribavirin Dosage
Significantly Affects Virological Response Rates in HCV Patients Treated
with Interferon/Ribavirin
10/27/03
Weight-based Dosing of PEG-Intron or Double the Dose Plus Ribavirin for
Naïve Patients and Double Dose PEG-Intron Plus Ribavirin for
Nonresponders and Relapsers
10/27/03
At 24 Weeks,
a Ribavirin Dose of 1000mg/day Appears to Offer No Advantages Over a
Dose of 800mg/day in HIV-HCV Coinfected Patients
11/10/03
In
Nonresponders at Week 48, High Dose PEG-Intron (3.0 mcg/kg/wk) Plus
Ribavirin Produces Similar Viral Clearance Rate as Standard Dose (1.5
mcg/kg/wk): The Renew Trial
11/17/03
|
|
Fibrosis
and Cirrhosis |
|
|
Patients with
Chronic Hepatitis C and Normal ALT Levels Show Impaired Quality of Life
But Significantly Lower Liver Inflammation and Fibrosis Progression
Compared to Patients with Elevated ALT
10/27/03
Race, Insulin Resistance, Visceral Adiposity and Hepatic Steatosis in
Genotype 1 HCV Patients
10/29/03
As HAART
Therapy Prolongs Survival, More HIV-HCV Coinfected Individuals May
Experience Morbidity and Death from Progressive Liver Disease
11/07/03
PEG-Intron Plus Ribavirin Improves Histology and Fibrosis in
Nonresponders to Conventional Interferon and Ribavirin
11/07/03
Treatment
with Pirfenidone for One Year Produces a Significant Reduction in
Necroinflammation and Steatosis in Patients with Liver Cirrhosis
11/19/03
HCV-specific
Immune Responses at Baseline Do Not Predict a Favorable Retreatment Outcome
in Patients with Advanced Disease
11/21/03
|
|
Adherence |
|
|
Adherence Rates Are
Higher and Discontinuation Rates Are Lower in Academic Centers Compared
to Community-based Centers
10/27/03
Epoetin Alfa
Significantly Improves Quality of Life in HCV Patients Receiving
Interferon plus Ribavirin and May Improve Adherence to Therapy
11/12/03
Page 10 |
|
|
